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To investigate the intrinsic effect of IL-15 expression on
CD8 responses we generated IL-15-deficient OT1 TCR-
transgenic mice. These mice died surprisingly at around
six months of age exhibiting grossly enlarged lymph
nodes, spleens and thymi. The affected organs harbored
mainly CD8+ T cells that were low for MHC class I,
expressed CD25 and CD24 as well as the co-stimulatory
receptors CD28, ICOS and PD1. This phenotype
resembled a sub-population of immature CD8 single-
positive thymocytes. These co-stimulatory receptor-posi-
tive CD8 cells (CD8cor) expanded after transfers into
mice that lacked NK cells due to IL-15 inhibition or anti-
body-mediated cell lysis, and NK cells caused in vivo lysis
of CD8cor cells. In contrast, the presence of IL-15-
dependent CD8+ T cells had no effect on CD8cor cell
expansion. In vivo expansions of CD8cor cells also
depended on the presence of CD11c-positive dendritic
cells while IL-2 activity was dispensable despite high
CD25 expression. These data suggest that NK cells pre-
vent the thymic escape of a sub-population of CD8 sin-
gle-positive thymocytes and their subsequent malignant
transformation in TCR-transgenic mice.
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